Memantine Solution
Product Images NDC 60505-6162

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Memantine (NDC 60505-6162). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Components (Components)

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure2 (Figure2)

The given text represents a chart depicting the cumulative percentage of patients using Placebo and Memantine HCI drugs. The chart displays the ADCS-ADL change from the baseline and the scale ranges from -20 to 25. However, the chart does not provide sufficient information to draw any conclusion from it.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

FDA Label Image

Figure5 (Figure5)

This text appears to be a chart showing the mean change from baseline in ADCS-ADL score for patients given a placebo/donepezil treatment versus memantine HC/donepezil treatment over the course of 12 weeks. The chart includes two categories, "Clinical Improvement" and "Clinical Decline," and displays the values for each treatment option at weeks 2, 4, 6, 8, 10, and 12. No further information is available.*

FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

This text represents a graph showing the mean change from baseline in SIB score over weeks of treatment for two groups. One group received placebo/donepezil and the other received Memantine HCI/Donepezil. The graph indicates that the group receiving the memantine HCI donepezil combination performed better as they experienced less clinical decline over the 24 weeks of treatment.*

FDA Label Image

Figure8 (Figure8)

The text describes a cumulative percentage of patients with a chart displaying two different treatments: placebo/donepezil and memantine HC/donepezil. The chart shows a line graph with a change from baseline represented by SIB. There are also some numbers on the chart axis.*

FDA Label Image

Step1 (Step1)

FDA Label Image

Step10 (Step10)

FDA Label Image

Step11 (Step11)

FDA Label Image

Step2 (Step2)

FDA Label Image

Step3 (Step3)

FDA Label Image

Step4 (Step4)

FDA Label Image

Step5 (Step5)

FDA Label Image

Step6 (Step6)

FDA Label Image

Step7 (Step7)

FDA Label Image

Step8 (Step8)

FDA Label Image

Step9 (Step9)

FDA Label Image

Bottle-label (Bottle Label)

This is a description of a medication called Memantine Hydrochloride Oral Solution, manufactured by Apotex Corp. Each 60mL bottle contains 2 mg/mL of memantine hydrochloride. The usual dosage and full prescribing information can be found in the package insert. The medication should be stored at a temperature between 20-25°C (68-77°F) in a tightly closed container. The medication is only available through a prescription and should be kept out of reach of children. The manufacturer is located in Toronto, Ontario, Canada.*

FDA Label Image

Carton (Carton)

This is a description of a medication called Memantine Hydrochloride Oral Solution manufactured by Apotex Corp. It is designated as B Only and has a concentration of 2g/e. The remaining text is not readable.*

FDA Label Image

Structural Formula (Memantine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.